If you were a patient, how is this going to make you feel any better taking the treatment! Oh you have a 5% better chance to get to 2 years, how about you have a 200% better chance or better yet, it's an actual cure.
DFFN:
" Results from the Phase 1/2 clinical trial in 59 patients showed that 36.3% of the full TSC dose patients were alive at two years, compared to historical two-year survival rates ranging from 27% to 30%. "
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.